ProMIS Neurosciences Files Special Meeting Proxy Material
For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877-452-7184 (+1-416-304-0211 outside North America) or email email@example.com.
TORONTO and CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that, further to its news release of October 7, 2021, it is filing today on SEDAR the management information circular for the special general meeting of shareholders (the “Special Meeting”) to be held on December 1, 2021.
At the Special Meeting, the shareholders will be asked to consider, and if deemed advisable, pass a special resolution authorizing the Board of Directors (the “Board”) to determine, at its discretion, to file articles of amendment to consolidate the Common Shares of the Company within a range from a ratio of thirty pre-consolidation Common Shares to one post-consolidation Common Share up to a ratio of sixty pre-consolidation Common Shares for one post-consolidated Common Share.
United States Stock Exchange Listing
Subject to shareholder approval, the Board intends to proceed with the share consolidation in furtherance of a listing of the Company’s shares on a stock exchange in the United States. Eugene Williams, the Company's Executive Chairman, adds that "The Board believes a listing on a stock exchange in the United States, in addition to potentially providing greater liquidity for our shareholders, should provide greater access to capital to help expedite the development of our potential therapies, including notably our lead program PMN310 for Alzheimer’s disease and the process of obtaining clinical validation of such potential therapies.”
The Company anticipates that the share consolidation may also result in certain additional benefits as a result of a higher post-consolidation market price for its Common Shares, including:
- enhancing the Company’s comparability against its peers on per share metrics;
- increasing the pool of investors to include those whose internal investment policies may prohibit or discourage them from purchasing stocks trading below a certain minimum price; and
- increasing analyst and broker interest as policies governing analysts and brokers may discourage following or recommending issuers with lower stock prices.
Any authority proposed to be granted to the Board to consolidate the shares is conditional upon the prior approval of the Toronto Stock Exchange (TSX). Notwithstanding approval of the resolution by shareholders and the TSX, the Board will retain the discretion to elect not to proceed with the share consolidation. Further, there can be no assurances that such a US listing will occur following either shareholder approval, TSX approval, the implementation of a consolidation of the shares or otherwise. Further, no assurance can be given that the Company will meet the quantitative or qualitative requirements to list on a stock exchange in the United States.
The full particulars of the special business are set out in the management information circular for the Special Meeting, which has been filed on SEDAR, is being sent to shareholders and can be found on the Company’s website at https://promisneurosciences.com/special-meeting-of-shareholders/.
Shareholder Information and Questions
Shareholders who have questions about the management information circular, or require assistance with voting their shares can contact the Company’s proxy solicitation agent, Laurel Hill Advisory Group:
Laurel Hill Advisory Group
North America Toll Free: 1-877-452-7184
Outside North America: 1-416-304-0211
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates—to predict novel targets, known as Disease Specific Epitopes, on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS Neurosciences, please consult the Company’s website at: www.promisneurosciences.com
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur including but not limited to statements related to the intent of the Company to pursue a potential listing of the Company’s Common Shares on an exchange in the United States, the Company’s ability to access capital improving as a result of a listing on a stock exchange in the United States, the additional benefits of a share consolidation and the Company obtaining the necessary regulatory approvals and satisfying the other requirements to file an IND and commence its clinical trials related to its lead program PMN310 soon thereafter.
Readers are cautioned that forward-looking statements are based on certain assumptions and are subject to known and unknown risks and uncertainties (both general and specific) that contribute to the possibility that the future events or circumstances contemplated by such forward-looking information will not occur. Such risks and uncertainties with respect to the forward-looking statements contained in this news release include, but are not limited to, the Company obtaining shareholder and Toronto Stock Exchange approval for a consolidation of its Common Shares, the Company’s ability to generally meet the quantitative and qualitative requirements to list its Common Shares on a stock exchange in the United States, the trading volumes in the Company’s Common Shares increasing as a result of a listing on a stock exchange in the United States, the Company’s ability to access capital improving as a result of a listing on a stock exchange in the United States, and the Company obtaining the necessary regulatory approvals and satisfying the other requirements to file an IND and commence its clinical trials related to its lead program PMN310 soon thereafter. Readers should also refer to the risk factors set forth in the Company’s continuous disclosure documents available at SEDAR (www.sedar.com). There can be no assurance that the plans, intentions or expectations upon which forward-looking statements are based will be realized. Actual results may differ, and the difference may be material and adverse to the Company and its shareholders. Therefore, readers should not place undue reliance upon such forward-looking statements. The Company does not intend, and does not assume any obligation, to update these forward-looking statements in order to reflect events or circumstances that may arise after the date of this news release except as required by applicable law or regulatory requirements.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Information on the total number of voting rights and shares26.11.2021 22:30:00 CET | Press release
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 26, 2021, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA(Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the exercise of subscription rights and the issue of new shares. Share capital: EUR 4,427,369.69 Total number of securities carrying voting rights: 25,772,359 (all ordinary shares) Total number of voting rights (= denominator): 25,772,359 (all relating to ordinary shares) Number of rights to subscribe to securities carrying voting rights not yet issued: 105 “2016 ESOP Warrants” issued on November 3, 2016, entitling their holders to subscribe to a total number of 52,500 securities carrying voting rights (all ordinary shares); 100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securit
Fobi to Host Shareholder Update and Earnings Webinar26.11.2021 17:57:56 CET | Press release
VANCOUVER, British Columbia, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the “Company” or “Fobi”), a leading data intelligence company using artificial intelligence to help clients turn real-time data into actionable insights and personalized customer engagement, is pleased to announce that Fobi will host a virtual-only shareholder update webinar on Thursday, December 2, 2021, from 9-10am PST (12-1pm EST). The shareholder update webinar will be facilitated by Rob Anson, CEO and Mark Lotz, CFO, who will review the company's most recent reporting period as well as discuss milestones, financial strength, M&A and the outlook for the remainder of the fiscal year. Fobi CEO Rob Anson and CFO Mark Lotz will facilitate pre-submitted and live-chat questions and answers. The company will answer pre-submitted and live questions at the conclusion of prepared remarks. Investors are asked to submit their questions to firstname.lastname@example.org. To register for this webinar, please visit
Nordic American Tankers Ltd (NYSE: NAT) – Purchase of shares by NAT board member Alexander Hansson (DUPLICATE)26.11.2021 16:25:26 CET | Press release
Friday, November 26, 2021 Dear Shareholders and Investors, Alexander Hansson, Board member in Nordic American Tankers Ltd and son of Herbjorn Hansson, the NAT Founder, Chairman and CEO, has today bought 50,000 share in NAT at $1.8564 per share. Following the transaction, Alexander Hansson privately owns 1,035,000 shares in Nordic American Tankers Ltd. As in the past, the Hansson family is the largest private shareholder in NAT. Alexander Hansson commented: “Uncertain times are normally good for our tankers. The recent set-back in stock markets is a good opportunity to accumulate shares” Sincerely, Herbjorn Hansson Founder, Chairman & CEO Nordic American Tankers Ltd. www.nat.bm CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective i
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS26.11.2021 16:20:00 CET | Press release
Bid procedure, 2021-12-03BondsSWEDISH GOVERNMENT: 1062. SE0013935319. 2031-05-12 SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24 Bid date2021-12-03Bid times09.00-10.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)1062: 500 mln SEK +/-250 mln SEK 1063: 500 mln SEK +/-250 mln SEK Highest permitted bid volume (corresponding nominal amount)1062: 500 mln SEK per bid 1063: 500 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2021-12-07Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-11-26 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions c
CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK TREASURY BILLS26.11.2021 16:20:00 CET | Press release
Bid procedure, 2021-12-01BillsSWEDISH T-BILL: SE0017084494. 2022-02-16 SWEDISH T-BILL: SE0015659529, 2022-03-16 Bid date2021-12-01Bid times10.00-11.00 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SE0017084494: 500 mln SEK +/-250 mln SEK SE0015659529: 1000 mln SEK +/-500 mln SEK Highest permitted bid volume (corresponding nominal amount)SE0017084494: 500 mln SEK per bid SE0015659529: 1000 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-12-03Delivery of billsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383 Stockholm, 2021-11-26 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms an
CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS26.11.2021 16:20:00 CET | Press release
Bid procedure, 2021-11-30BondsKOMMUNINVEST I SVERIGE: 2311. SE0010948240. 2023-11-13 KOMMUNINVEST I SVERIGE: 2505, SE0011414010, 2025-05-12 KOMMUNINVEST I SVERIGE: G23, XS1897258098, 2023-06-01 BidsBids on interest and volume are entered via Bloomberg Bond Auction SystemBid date2021-11-30Bid times10.00-11.00Requested volume (corresponding nominal amount)2311: 750 mln SEK +/-400 mln SEK 2505: 500 mln SEK +/-250 mln SEK G23: 250 mln SEK +/-150 mln SEK Highest permitted bid volume (corresponding nominal amount)2311: 750 mln SEK per bid 2505: 500 mln SEK per bid G23: 250 mln SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 50 million per bidExpected allocation timeNot later than 11.15 (CET/CEST) on the Bid dateDelivery and payment date2021-12-02Delivery of bondsTo the Riksbank's account in Euroclear Sweden AB's securities settlement system 1 4948 6383General Terms and ConditionsGeneral Terms and Conditions General Terms and Conditions för the Riksbank’s Purchases o
CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER26.11.2021 16:20:00 CET | Press release
Bid procedure, 2021-12-01CertificateCommercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date. i.e. with the latest maturity date as of 2022-06-01 Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 2021-11-19 BidsCounterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date2021-12-01Bid times09.00-09.30 (CET/CEST) on the Bid dateRequested volume (corresponding nominal amount)SEK 4 billionHighest permitted bid volume (corresponding nominal amount)The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 4 billion. No bid may contain Commercial paper in excess of SEK 250 million issued by the s